assay (Clin. Chem., 43, 1944-1951 (1997)), and the like. However, a highly sensitive and expensive assay device is necessary for these methods, and the operation of the assay is complicated, costly, and time-consuming.

REMARKS

Claims 1-10 are active in the present application. The specification has been amended on page 3 to provide the correct page numbers to the cited reference. The amendment corrects an obvious typographical error. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.
Registration No. 50,238

22850
(703) 413-3000
Fax #: (703)413-2220
NFO/SUK/sjh
I:\atty\SUKOS\221513US-PR.WPD

Marked-Up Copy
Serial No: 10/088,524

Amendment Filed on
Herewith:

IN THE TITLE

Please delete the title and replace with the following title.

[METHOD FOR ASSAYING GLYCATED PROTEIN]

--METHOD OF ASSAYING GLYCOPROTEIN--

IN THE SPECIFICATION

Please replace the paragraph on page 3, lines 4-13 with the following paragraph:

--At present, methods proposed for assaying glycated hemoglobin (HbAlc) include a method in which glycated hemoglobin is directly assayed in that state by electrospray-ionization mass spectrometry (Clinical Test, 42, 340-343 (1997)), a method in which endoproteinase Glu-C is allowed to act on glycated hemoglobin, a liberated α-glycated hexapeptide derived from β-subunit (α-amino group of an amino acid at the amino terminus of hexapeptide is glycated) is fractionated by reversed phase high performance liquid chromatography, and the content thereof is determined through mass spectrometry analysis to assay (Clin. Chem., 43, [1994-1951] 1944-1951 (1997)), and the like. However, a highly sensitive and expensive assay device is necessary for these methods, and the operation of the assay is complicated, costly, and time-consuming.--